Core Viewpoint - Furuya Medical Technology (01696) experienced a significant decline of over 11%, with a current price of HKD 6.18 and a trading volume of HKD 18.245 million following the release of its mid-year results for 2025, indicating challenges in the North American market and a decrease in profitability [1][1][1] Financial Performance - The company reported revenues of USD 165 million for the mid-year period, reflecting a year-on-year decrease of 1.9% [1] - Net profit attributable to shareholders was USD 6.426 million, down 41.3% year-on-year [1] - Basic earnings per share were USD 0.0137 [1] Market Conditions - The decline in revenue is primarily attributed to challenging conditions in the North American market, characterized by high interest rates and weak consumer demand [1] - Transportation delays due to regional tensions in June also contributed to a slight delay in revenue recognition [1] International Market Growth - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Order Reserves and Profitability - As of June 30, 2025, the company's order reserves remained robust, increasing by several million dollars compared to the same period in 2024 [1] - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period, primarily due to a strategic shift towards core professional and high-end products, which have higher material costs due to advanced technology specifications [1][1]

Core Viewpoint - Furuya Medical Technology (01696) reported a revenue of $165 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 1.9% [1] - The company's net profit attributable to shareholders was $6.426 million, down 41.3% year-on-year, with basic earnings per share at 1.37 cents [1] Group 1: Revenue and Market Conditions - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending [1] - Transportation delays in June due to regional tensions also contributed to a slight delay in revenue recognition [1] - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Group 2: Profitability and Cost Structure - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period [1] - The reduction in gross margin is mainly due to a strategic shift in the product mix towards core professional-grade and precision high-end products, which have higher material costs due to the use of top-tier technology specifications [1] - The decline in revenue contribution from North America also impacted the overall profitability [1] Group 3: Order Backlog - As of June 30, 2025, the order backlog remains robust, increasing by several million dollars compared to the same period in 2024 [1]

Core Viewpoint - Furuya Medical Technology (01696) reported a revenue of $165 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 1.9% [1] - The company's net profit attributable to shareholders decreased by 41.3% to $6.426 million, with basic earnings per share at 1.37 cents [1] Group 1: Revenue and Market Conditions - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending [1] - Transportation delays in June due to regional tensions also contributed to a slight delay in revenue recognition [1] - Excluding the adverse factors in the North American market, Furuya Medical Technology's international market achieved a growth of 7.1% compared to the same period in 2024 [1] Group 2: Profitability and Cost Structure - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period [1] - The reduction in gross margin is mainly due to a strategic shift towards core professional-grade and precision high-end products, which have higher material costs due to the use of top-tier technology specifications [1] - The decline in revenue contribution from North America also impacted the overall profitability [1] Group 3: Order Backlog - As of June 30, 2025, the order backlog remains robust, with an increase of several million dollars compared to the same period in 2024 [1]